Moreover, to more precisely define prognosis and better predict the benefits of adjuvant treatment in mCRC, a quantitative and qualitative assessment of NK cell based on KIR/HLA genotype should be related to known CRC-associated genetic markers (i.e. KRAS mutational status, microsatellite-unstable CRC). Here, KRAS is linked to colorectal carcinoma.